Investigating biomarkers of Staphylococcus aureus bacteremia in patients - School of Pharmacy

The Centers for Disease Control identifies methicillin-resistant S. aureus (MRSA) as a serious health threat with greater than 100,000 invasive infections and 20,000 patient deaths annually in the United States. Despite recent advancements in available treatment options for methicillin-sensitive S.

School of Pharmacy and Pharmaceutical Sciences 2020-21 Annual Report by BinghamtonU - Issuu

Mechanism and pharmacodynamics of glyco/lipopeptide synergy with older antimicrobials - School of Pharmacy

Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice, Journal of Nanobiotechnology

Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

Frontiers Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies

Impact of infectious diseases consultation on the management of Staphylococcus aureus bacteraemia in children

Rescuing the Last-Line Polymyxins: Achievements and Challenges

Staphylococcus aureus Bacteremia in Adults

Pathogens, Free Full-Text

Antimicrobial resistance - Wikipedia